19.81
+0.01(+0.05%)
Currency In USD
| Previous Close | 19.8 |
| Open | 19.8 |
| Day High | 20.58 |
| Day Low | 19.1 |
| 52-Week High | 61.07 |
| 52-Week Low | 1.4 |
| Volume | 398,719 |
| Average Volume | 205,480 |
| Market Cap | 369.9M |
| PE | -6.31 |
| EPS | -3.14 |
| Moving Average 50 Days | 20.71 |
| Moving Average 200 Days | 31.11 |
| Change | 0.01 |
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
GlobeNewswire Inc.
May 17, 2025 2:40 PM GMT
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)In new echocardiographic
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the acti
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Thera